View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 15, 2022updated 27 Jul 2022 12:45pm

Health Canada grants approval for Moderna’s Covid-19 vaccine in children

In Phase II/III KidCOVE trial, two doses of the vaccine offered strong neutralising antibody response in the young children.

Health Canada has granted approval for the usage of Moderna’s messenger RNA (mRNA) Covid-19 vaccine, Spikevax, in a 25µg two-dose regimen for active immunisation to prevent Covid-19 in children aged six months to five years. 

So far, children aged below five years were not eligible to receive the Covid-19 vaccine in Canada. 

The two-dose initial vaccine regimen in children of this age group is completed in one month, which is the same dosing schedule in adults, adolescents and children aged above five years.

According to the positive interim findings from the Phase II/III KidCOVE clinical trial, a two-dose primary series of mRNA-1273 offered a strong neutralising antibody response in the young children with a favourable safety profile. 

The KidCOVE trial was carried out at eight Canadian trial sites involving 414 children aged below five years.

The antibody titers in the pre-specified age sub-groups comprising six- to 23-month and two- to five-year-old children met the statistical criteria for similarity with adults in the COVE study, meeting the primary objective of the trial. 

Following two doses of the vaccine, initial efficacy analysis on PCR-confirmed cases during the Omicron wave showed efficacy estimates against Omicron in young children were in line with those in adults. 

In March this year, the regulatory agency approved Spikevax for active immunisation to prevent Covid-19 in people aged six years and above.

Moderna Canada president and general manager Patricia Gauthier said: “This decision from Health Canada confirms the effectiveness and safety of Moderna’s vaccine in this final and important age group.

“With this announcement, parents and caregivers now have an option to protect these very young children, a group at high risk of infection and where additional health prevention measures like wearing masks may not always be feasible.”

In June this year, the company signed an agreement with the European Commission to amend initially agreed contractual supply schedules for Covid-19 vaccine booster product or updated booster vaccine candidate.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Optimise your cell therapy process: a guide to cell thawing

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology